Ye Weiguo, serving as the Chief Operating Officer of Gyre Therapeutics, Inc. (NASDAQ: GYRE), executed a series of stock transactions resulting in the sale of 20,918 shares of the company's common stock. The total value derived from these sales stands at approximately $128,885. The transactions were executed across two distinct dates, June 9 and June 10, 2026, following the exercise of vested stock options. This sequence of events represents a standard mechanism for executives to realize value from equity compensation, though it occurs while the broader market valuation of the company remains below its recent peaks.
The insider activity is defined by two specific transaction dates. On June 9, 2026, Mr. Ye sold 14,500 shares. This was followed on June 10, 2026, by the sale of an additional 6,418 shares. The pricing structure for these sales varied slightly across the two days. The shares sold on June 9 carried a weighted average sale price of $6.14, with individual transaction prices ranging from $6.0597 to $6.19. The subsequent sales on June 10 occurred at a weighted average price of $6.21, with individual prices ranging between $6.11 and $6.30. The aggregate value from these specific sales events totals $128,885.
Crucially, these sales were not executed from open market purchases but were the result of prior option exercises. Prior to selling the shares, Mr. Ye acquired the identical number of shares by exercising vested stock options. He acquired 14,500 shares on June 9 and 6,418 shares on June 10. The acquisition price for these underlying shares was fixed at $0.75 per share. This resulted in a total acquisition cost of approximately $15,688 for the entire block of shares. The spread between the exercise price and the sale price represents the realized value of the compensation package.
Following the execution of these sales, Mr. Ye's direct ownership position in Gyre Therapeutics common stock stands at 700,000 shares. In addition to his direct holdings, he maintains a significant derivative position, holding 841,501 derivative shares in the form of stock options. This remaining option portfolio indicates continued alignment with the company's long-term performance metrics, even as immediate liquidity events occur.
The stock itself is currently trading at $6.06. This price point reflects a decline of nearly 4% over the past month. Furthermore, the current valuation sits roughly 30% below its 52-week high of $9.42. Despite this recent price weakness, analyst price targets remain elevated, suggesting a disconnect between current market pricing and fundamental expectations. Analysts maintain price targets ranging between $18 and $20 per share. InvestingPro analysis suggests that the stock currently appears overvalued relative to its calculated Fair Value, highlighting the conflicting signals between analyst projections and current market trading levels.
These insider transactions occur within a period of significant operational expansion for Gyre Therapeutics. The company has announced the completion of its acquisition of Cullgen Inc., a clinical-stage biopharmaceutical company. This transaction was valued at approximately $300 million. As a direct result of this acquisition, Dr. Ying Luo, the former CEO of Cullgen, has been appointed as the President and CEO of Gyre. Ping Zhang continues to serve as the Chairman of the Board of Directors, maintaining continuity in board leadership during this executive transition.
Simultaneously, Gyre Therapeutics is advancing its clinical pipeline through regulatory channels in China. The China National Medical Products Administration has accepted the New Drug Application for F351, a treatment designed for chronic hepatitis B-induced liver fibrosis. This acceptance follows the administration's earlier decision to grant the drug priority review status, which typically accelerates the regulatory timeline. Gyre submitted this application through its majority-owned subsidiary, Gyre Pharmaceuticals Co., Ltd. This marks the third submission accepted for review by this specific regulatory body, indicating a pattern of successful regulatory engagement.
While the insider sale represents a standard liquidity event for the COO, the broader context involves substantial changes to the company's capital structure and leadership. The $300 million acquisition and the regulatory progress on F351 suggest a pivot toward larger-scale operations and international market expansion. However, the current stock price of $6.06 remains significantly detached from the analyst price targets of $18 to $20, presenting a wide valuation gap that investors must reconcile.